Table 4 Tumor response of different treatment modalities (n=26)

TKI+PD-1/PD-L1 monoclonal antibody

1 (3.8)

1 (100)

1 (100)

 Sorafenib + Sintilimab

1

1 (100)

1 (100)

Locoregional therapies + TKI

4 (15.4)

1 (25)

3 (75)

 TACE + Lenvatinib

3

0 (0)

1 (33.3)

 TACE + Radiotherapy+ Lenvatinib

1

0 (0)

1 (100)

Locoregional therapies +TKI + Anti-PD-1

21 (80.8)

10 (47.6)

17 (81)

 HAIC + Lenvatinib + Camrelizumab

12

5 (41.7)

8 (66.7)

 HAIC + Apatinib + Camrelizumab

3

2 (66.7)

3 (100)

 TACE + Sorafenib +Sintilimab

1

0 (0)

1 (100)

 TACE + Sorafenib + Camrelizumab

2

2 (100)

2 (100)

 TACE + Lenvatinib + Camrelizumab

1

0 (0)

1 (100)

 TACE + Apatinib + Camrelizumab

2

1 (50)

2 (100)